{"protocolSection":{"identificationModule":{"nctId":"NCT06472635","orgStudyIdInfo":{"id":"IIT20230408B-R2"},"organization":{"fullName":"Zhejiang University","class":"OTHER"},"briefTitle":"a Neo-adjuvant Chemotherapy Immunotherapy in Resectable ESCC Study","officialTitle":"A Retrospective, Multicenter, Single-arm Real-world Study on a New Adjuvant Chemotherapy Combined With Immune Inhibitors for Resectable Esophageal Squamous Cell Carcinoma (ESCC)","acronym":"ANACIIRE-1"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-03-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-09-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-10-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-16","studyFirstSubmitQcDate":"2024-06-24","studyFirstPostDateStruct":{"date":"2024-06-25","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-24","lastUpdatePostDateStruct":{"date":"2024-06-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Zhengliang.Tu","investigatorTitle":"Director of General Thoracic Surgery Department / Chief Doctor","investigatorAffiliation":"Zhejiang University"},"leadSponsor":{"name":"Zhejiang University","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Research Purpose 1: To evaluate the therapeutic efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in the treatment of resectable locally advanced esophageal squamous cell carcinoma (ESCC) in the real-world setting.\n\nResearch Purpose 2: To analyze the influencing factors of the therapeutic effect of neoadjuvant immunotherapy combined with chemotherapy in the treatment of resectable locally advanced esophageal squamous cell carcinoma (ESCC) in the real-world setting.\n\nResearch Purpose 3: To understand the treatment patterns of neoadjuvant immunotherapy combined with chemotherapy in the treatment of resectable locally advanced ESCC in the","detailedDescription":"Research Purpose 1: To evaluate the therapeutic efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in the treatment of resectable locally advanced esophageal squamous cell carcinoma (ESCC) in the real-world setting.\n\nResearch Purpose 2: To analyze the influencing factors of the therapeutic effect of neoadjuvant immunotherapy combined with chemotherapy in the treatment of resectable locally advanced esophageal squamous cell carcinoma (ESCC) in the real-world setting.\n\nResearch Purpose 3: To understand the treatment patterns of neoadjuvant immunotherapy combined with chemotherapy in the treatment of resectable locally advanced ESCC in the"},"conditionsModule":{"conditions":["The Neoadjuvant Treatment for Resectable Esophageal Squamous Cell Carcinoma"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"CASE_CONTROL","timePerspective":"RETROSPECTIVE"},"enrollmentInfo":{"count":95,"type":"ESTIMATED"}},"outcomesModule":{"primaryOutcomes":[{"measure":"Pathological Complete Response (pCR)","description":"pCR is defined as the ratio of residual viable tumor cells being 0 in the primary tumor and sampled lymph nodes.","timeFrame":"12 months"}],"secondaryOutcomes":[{"measure":"Resection Rate","description":"R0 resection refers to the complete removal of the tumor, with negative microscopic margins, indicating no residual tumor; no cancer cells are found on the cutting line under pathological examination.","timeFrame":"12 months"}],"otherOutcomes":[{"measure":"ORR","description":"Defined as the proportion of patients achieving complete response (CR) or partial response (PR) among all patients, with efficacy evaluation based on the RECIST 1.1 criteria.","timeFrame":"12 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nAge â‰¥ 18 years (including 18 years old); ECOG 0 or 1; Patients with esophageal squamous cell carcinoma judged to be resectable (including initially non-resectable) by the researcher Received esophageal radical surgery and neoadjuvant immune chemotherapy before surgery Clinical staging belongs to: T1b-4NanyM0;\n\nExclusion Criteria:\n\nPatients without complete medical information; Received other anti-tumor treatment before surgery; Received radiotherapy treatment; Judged by the researcher, have other conditions unsuitable for participating in this clinical study.\n\nHide hide Contacts/Locations","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Esophageal Squamous Cell Carcinoma (ESCC), with a follow-up cutoff date of March 2024, is expected to take 6 months for data cleaning and analysis, and the data collection and analysis are anticipated to be completed in September 2024.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"locations":[{"facility":"The first affiliated hospital of Zhejiang University","city":"Hangzhou","state":"Zhejiang","zip":"3210002","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000002277","term":"Carcinoma"},{"id":"D000002294","term":"Carcinoma, Squamous Cell"},{"id":"D000077277","term":"Esophageal Squamous Cell Carcinoma"}],"ancestors":[{"id":"D000009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D000009370","term":"Neoplasms by Histologic Type"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000018307","term":"Neoplasms, Squamous Cell"},{"id":"D000004938","term":"Esophageal Neoplasms"},{"id":"D000005770","term":"Gastrointestinal Neoplasms"},{"id":"D000004067","term":"Digestive System Neoplasms"},{"id":"D000009371","term":"Neoplasms by Site"},{"id":"D000006258","term":"Head and Neck Neoplasms"},{"id":"D000004066","term":"Digestive System Diseases"},{"id":"D000004935","term":"Esophageal Diseases"},{"id":"D000005767","term":"Gastrointestinal Diseases"}],"browseLeaves":[{"id":"M5534","name":"Carcinoma","asFound":"Carcinoma","relevance":"HIGH"},{"id":"M5550","name":"Carcinoma, Squamous Cell","asFound":"Squamous Cell Carcinoma","relevance":"HIGH"},{"id":"M1733","name":"Esophageal Squamous Cell Carcinoma","asFound":"Esophageal Squamous Cell Carcinoma","relevance":"HIGH"},{"id":"M12320","name":"Neoplasms, Glandular and Epithelial","relevance":"LOW"},{"id":"M12315","name":"Neoplasms by Histologic Type","relevance":"LOW"},{"id":"M20451","name":"Neoplasms, Squamous Cell","relevance":"LOW"},{"id":"M8088","name":"Esophageal Neoplasms","relevance":"LOW"},{"id":"M7256","name":"Digestive System Neoplasms","relevance":"LOW"},{"id":"M8886","name":"Gastrointestinal Neoplasms","relevance":"LOW"},{"id":"M9348","name":"Head and Neck Neoplasms","relevance":"LOW"},{"id":"M8883","name":"Gastrointestinal Diseases","relevance":"LOW"},{"id":"M7255","name":"Digestive System Diseases","relevance":"LOW"},{"id":"M8085","name":"Esophageal Diseases","relevance":"LOW"},{"id":"T2141","name":"Esophageal Cancer","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC06","name":"Digestive System Diseases"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M2853","name":"Immunomodulating Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}